KRYS Stock: Price, Earnings History and SEC Filings
Krystal Biotech, Inc. (KRYS) last traded at $332.29, up 2.38% on the latest session and down 0.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.79 against an analyst estimate of $1.70, a beat of 5.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
KRYS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $1.79 | $1.70 | +5.29% |
| Mar 2026 | May 4, 2026 | $1.83 | $1.45 | +26.21% |
| Dec 2025 | Feb 17, 2026 | $1.70 | $1.62 | +4.94% |
| Sep 2025 | Nov 3, 2025 | $2.66 | $1.12 | +137.50% |
KRYS beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How KRYS reacts to earnings
Across its last 8 earnings releases, KRYS moved 6.7% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | Before open | -8.37% |
| 2026-02-17 | Before open | +4.12% |
| 2026-01-12 | Before open | +4.10% |
| 2025-11-03 | Before open | +0.17% |
| 2025-08-04 | Before open | -14.04% |
| 2025-05-06 | Before open | -14.06% |
| 2024-11-04 | Before open | -3.14% |
| 2024-08-05 | Before open | -5.85% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
KRYS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $389M | $205M | $189M | 52.6% | $6.84 |
| 2024 | $291M | $89M | $119M | 30.7% | $3.00 |
| 2023 | $51M | $11M | -$101M | 21.6% | $0.39 |
| 2022 | $0 | -$140M | -$154M | – | $-5.49 |
| 2021 | $0 | -$70M | -$116M | – | $-3.13 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for KRYS
- 8-K · Oct 15, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 3, 2026
- 8-K · Jul 21, 2026Other events, Financial statements and exhibits
- 8-K · May 20, 2026Shareholder vote
- 8-K · May 4, 2026Financial statements and exhibits
- 10-Q · May 4, 2026
- DEF 14A · Apr 3, 2026
- 8-K · Feb 17, 2026Results of operations
- 10-K · Feb 17, 2026
Insider filing activity
KRYS insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
KRYS news
- Has The Story Under Krystal Biotech Stock Run Out?Oct 28, 2026 · trefis.com
- Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings GrowthOct 27, 2026 · finance.yahoo.com
- Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out forOct 26, 2026 · finance.yahoo.com
- Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026Oct 22, 2026 · finance.yahoo.com
- Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsightOct 21, 2026 · finance.yahoo.com
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). Its fiscal year ends in December.